18F-FDG PET/CT在新辅助化疗免疫治疗后非小细胞肺癌纵隔淋巴结病变评估中的临床效用
这项多中心研究纳入181例(化疗免疫治疗86例、化疗95例)非小细胞肺癌患者,评估PET/CT预测新辅助化疗免疫治疗后ypN2病的效能,敏感度0.667、特异度0.835、准确率0.779、AUC 0.751;ypN2患者中PET/CT-N2(+)是独立预后因素。
要点
- PET/CT预测ypN2病的敏感度0.667、特异度0.835、准确率0.779、AUC 0.751。
- 真阳性N2淋巴结SUVmax均值6.024高于假阳性2.672(p < 0.001)。
- ypN2患者中PET/CT-N2(+)是独立预后因素,化疗免疫治疗组p = 0.023、化疗组p = 0.010。
核心结论
- PET/CT是评估接受新辅助化疗免疫治疗的非小细胞肺癌患者纵隔再分期的准确无创检查,ypN2且PET/CT-N2(+)患者较PET/CT-N2(-)者为独立预后因素。
研究设计与样本
- 多中心研究纳入4家机构的181例连续患者(化疗免疫治疗86例、化疗95例),每例术前接受PET/CT扫描并完成完整切除及系统淋巴结清扫。
关键影像表现/征象
- 真阳性患者N2淋巴结SUVmax均值6.024,假阳性患者为2.672(p < 0.001)。
- 化疗免疫治疗组与化疗组真阳性病例SUVmax分别为7.671与5.976(p = 0.365),假阳性病例分别为2.433与2.339(p = 0.990)。
诊断标准与关键数值
- PET/CT预测ypN2病的敏感度0.667、特异度0.835、准确率0.779、AUC 0.751。
临床应用与阅片要点
- PET/CT可作为预测新辅助化疗免疫治疗后ypN2病的有效无创工具。
- ypN2患者中PET/CT-N2(+)是强且独立的预后因素。
- 原文建议在临床实践中鼓励应用PET/CT进行再分期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The performance of positron emission tomography/computed tomography (PET/CT) for the prediction of ypN2 disease in non-small cell lung cancer (NSCLC) after neoadjuvant chemoimmunotherapy has not been reported. This multicenter study investigated the utility of PET/CT to assess ypN2 disease in these patients.
METHODS: A total of 181 consecutive patients (chemoimmunotherapy = 86, chemotherapy = 95) at four institutions were enrolled in this study. Every patient received a PET/CT scan prior to surgery and complete resection with systematic nodal dissection. The diagnostic performance was evaluated through area under the curve (AUC). Kaplan-Meier method and Cox analysis were performed to identify the risk factors affecting recurrences.
RESULTS: The sensitivity, specificity, and accuracy of PET/CT for ypN2 diseases were 0.667, 0.835, and 0.779, respectively. Therefore, the AUC was 0.751. Compared with the false positive cases, the mean value of max standardized uptake value (SUVmax) (6.024 vs. 2.672, p < 0.001) of N2 nodes was significantly higher in true positive patients. Moreover, the SUVmax of true positive (7.671 vs. 5.976, p = 0.365) and false (2.433 vs. 2.339, p = 0.990) positive cases were similar between chemoimmunotherapy and chemotherapy, respectively. Survival analysis proved that pathologic N (ypN) 2 patients could be stratified by PET/CT-N2(+ vs. -) for both chemoimmunotherapy (p = 0.023) and chemotherapy (p = 0.010).
CONCLUSIONS: PET/CT is an accurate and non-invasive test for mediastinal restaging of NSCLC patients who receive neoadjuvant chemoimmunotherapy. The ypN2 patients with PET/CT-N2( +) are identified as an independent prognostic factor compared with PET/CT-N2(-).
CLINICAL RELEVANCE STATEMENT: Imaging with 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) plays an integral role during disease diagnosis, staging, and therapeutic response assessments in patients with NSCLC. PET/CT could be an effective non-invasive tool for predicting ypN2 diseases after neoadjuvant chemoimmunotherapy.
KEY POINTS: • PET/CT could serve as an effective non-invasive tool for predicting ypN2 diseases. • The ypN2 patients with PET/CT-N2( +) were a strong and independent prognostic factor. • The application of PET/CT for restaging should be encouraged in clinical practice.
引用
- Zhang L, E H, Huang J, et al. Clinical utility of [18F]FDG PET/CT in the assessment of mediastinal lymph node disease after neoadjuvant chemoimmunotherapy for non-small cell lung cancer. Eur Radiol. 2023. PMID: 37464112. doi:10.1007/s00330-023-09910-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。